RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio's products are high-volume, cost-effective, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and cost savings for customers. RoosterBio's innovative products and collaborative relationships are ushering in a new era of productivity and standardization into the field.
How is RoosterBio contributing to the future of healthcare?
RoosterBio is revolutionizing the future of healthcare by radically simplifying the use of human mesenchymal stem/stromal cells (hMSCs) for regenerative medicine product development. RoosterBio’s standardized MSC bioprocess systems empowers researchers and product developers across a spectrum of therapeutic approaches from cell and gene therapy, tissue engineering, extracellular vesicles, to novel medical devices. The company works alongside industry partners, academics, and clinicians to advance MSC research and therapies across the globe.
RoosterBio is reducing time-to-market by compressing customer product development timelines and creating a clear path from research to cGMP manufacturing with their standardized MSC bioprocess systems. The company’s deep expertise in MSC manufacturing and product characterization is enabling customers and collaborators in the regenerative medicine industry to develop successful applications of MSC technology. Going forward, RoosterBio’s solutions, an industrialized supply chain of high-quality hMSCs paired with productive bioprocess media and key process parameters, will fuel the tens to hundreds of next-generation cell-based therapeutics.